All Outputs (2)

Efficacy and safety of autologous cell therapies for knee cartilage defects (autologous stem cells, chondrocytes or the two): randomized controlled trial design. (2017)
Journal Article
Richardson, J. B., Wright, K. T., Wales, J., Herman Kuiper, J., McCarthy, H. S., Gallacher, P., …Roberts, S. (2017). Efficacy and safety of autologous cell therapies for knee cartilage defects (autologous stem cells, chondrocytes or the two): randomized controlled trial design. Regenerative Medicine, 12(5), 493-501. https://doi.org/10.2217/rme-2017-0032

AIM: The main aim of this trial is to test the safety and efficacy of autologous stromal/stem cells, chondrocytes or the two combined in the treatment of knee cartilage defects. PATIENTS & METHODS: Patients with symptomatic chondral/osteochondral def... Read More about Efficacy and safety of autologous cell therapies for knee cartilage defects (autologous stem cells, chondrocytes or the two): randomized controlled trial design..

Human articular chondrocytes retain their phenotype in sustained hypoxia whilst normoxia promotes their immunomodulatory capacity (2017)
Presentation / Conference
Mennan, C., Owen, S., Garcia, J., McCarthy, H., Banerjee, R., Roberts, S., & Richardson, J. (2017, March). Human articular chondrocytes retain their phenotype in sustained hypoxia whilst normoxia promotes their immunomodulatory capacity. Poster presented at British Society for Matrix Biology “The Grey Area – Age and the Extracellular Matrix”

Introduction The maintenance of chondrogenic phenotype in human articular chondrocytes grown in continuous normoxic (21% O2) and hypoxic (2% O2) conditions was assessed, with the aim of finding the best environment for culturing cells destined for ca... Read More about Human articular chondrocytes retain their phenotype in sustained hypoxia whilst normoxia promotes their immunomodulatory capacity.